Epileptogenesis

Last updated

Epileptogenesis is the gradual process by which a typical brain develops epilepsy. [1] Epilepsy is a chronic condition in which seizures occur. [2] These changes to the brain occasionally cause neurons to fire in an abnormal, hypersynchronous manner, known as a seizure . [3]

Contents

Causes

The causes of epilepsy are broadly classified as genetic, structural/metabolic, or unknown. [4] Anything that causes epilepsy causes epileptogenesis, because epileptogenesis is the process of developing epilepsy. Structural causes of epilepsy include neurodegenerative diseases, traumatic brain injury, stroke, brain tumor, infections of the central nervous system, and status epilepticus (a prolonged seizure or a series of seizures occurring in quick succession). [5]

Latent period

After a brain injury occurs, there is frequently a "silent" or "latent period" lasting months or years in which seizures do not occur; [6] Canadian neurosurgeon Wilder Penfield called this time between injury and seizure "a silent period of strange ripening". [7] During this latent period, changes in the physiology of the brain result in the development of epilepsy. [6] This process, during which hyperexcitable neural networks form, is referred to as epileptogenesis. [6] If researchers come to better understand epileptogenesis, the latent period may allow healthcare providers to interfere with the development of epilepsy or to reduce its severity. [6]

Pathophysiology

Changes that occur during epileptogenesis are poorly understood but are thought to include cell death, axonal sprouting, reorganization of neural networks, alterations in the release of neurotransmitters, and neurogenesis. [5] These changes cause neurons to become hyperexcitable and can lead to spontaneous seizures. [5]

Brain regions that are highly sensitive to insults and can cause epileptogenesis include temporal lobe structures such as the hippocampus, the amygdala, and the piriform cortex. [6]

Neural reorganization

In addition to chemical processes, the physical structure of neurons in the brain may be altered. In acquired epilepsy in both humans and animal models, pyramidal neurons are lost, and new synapses are formed. [3]

Hyperexcitability, a characteristic feature of epileptogenesis in which the likelihood that neural networks will be activated is increased, may be due to loss of inhibitory neurons, such as GABAergic interneurons, that would normally balance out the excitability of other neurons. [3] Neuronal circuits that are epileptic are known for being hyperexcitable and for lacking the normal balance of glutamatergic neurons (those that usually increase excitation) and GABAergic ones (those that decrease it). [6] In addition, the levels of GABA and the sensitivity of GABAA receptors to the neurotransmitter may decrease, resulting in less inhibition. [3]

Another proposed mechanism for epileptogenesis in TBI is that damage to white matter causes hyperexcitability by effectively undercutting the cerebral cortex. [8]

Glutamate receptor activation

It is believed that activation of biochemical receptors on the surfaces of neurons is involved in epileptogenesis; these include the TrkB neurotrophin receptor and both ionotropic glutamate receptors and metabotropic glutamate receptors (those that are directly linked to an ion channel and those that are not, respectively). [2] Each of these types of receptor may, when activated, cause an increase in the concentration of calcium ions (Ca2+) within the area of the cell on which the receptors are located, and this Ca2+ can activate enzymes such as Src and Fyn that may lead to epileptogenesis. [2]

Excessive release of the neurotransmitter glutamate is widely recognized as an important part of epileptogenesis early after a brain injury, including in humans. [6] Excessive release of glutamate results in excitotoxicity, in which neurons are excessively depolarized, intracellular Ca2+ concentrations increase sharply, and cellular damage or death results. [6] Excessive glutamatergic activity is also a feature of neuronal circuits after epilepsy has developed, but glutamate does not appear to play an important role in epileptogenesis during the latent period. [6] Another factor in hyperexcitability may include a decrease in the concentration of Ca2+outside cells (i.e. in the extracellular space) and a decrease in the activity of ATPase in glial cells. [3]

Blood brain barrier disruption

Blood brain barrier (BBB) disruption occurs in high prevalence following all brain lesions that may cause post injury epilepsy such as stroke, traumatic brain injury, brain infection or brain tumor. [9] BBB disruption was shown to underlay epileptogenesis by several experimental models. [10] [11] Furthermore, it was shown that albumin, the most frequent protein in the serum is the agent that leaks from the blood into the brain parenchyma under BBB disruption conditions and induces epileptogenesis by activation of the transforming growth factor beta receptor on astrocytes. [12] [13] [14] Additional investigation exposed that this process is mediated by a unique inflammatory pattern [13] [15] and the formation of excitatory synapses. [16] Pathogenic influence was attributed also to the extravasation of other blood born substances such as hemosiderin or iron. [8] Iron from hemoglobin, a molecule in red blood cells, can lead to the formation of free radicals that damage cell membranes; this process has been linked to epileptogenesis. [17]

Treatment

A major goal of epilepsy research is the identification of therapies to interrupt or reverse epileptogenesis. Studies largely in animal models have suggested a wide variety of possible antiepileptogenic strategies although, to date, no such therapy has been demonstrated to be antiepileptogenic in clinical trials. [18] Some anticonvulsant drugs, including levetiracetam and ethosuximide have shown promising activity in animal models. Other promising strategies are inhibition of interleukin 1β signaling by drugs such as VX-765; modulation of sphingosine 1-phosphate signaling by drugs such as fingolimod; activation of the mammalian target of rapamycin (mTOR) by drugs such as rapamycin; the hormone erythropoietin; and, paradoxically, drugs such as the α2 adrenergic receptor antagonist atipamezole and the CB1 cannabinoid antagonist SR141716A (rimonabant) with proexcitatory activity. The discovery of the role played by TGF-beta activation in epileptogenesis raised the hypothesis that blocking this signaling may prevent epileptogenesis. Losartan, a commonly used drug for the treatment of hypertension was shown to prevent epilepsy and facilitate BBB healing in animal models. Testing the potential of antiepileptogenic agents (e.g. losartan) or BBB healing drugs necessitates biomarkers for patients selection and treatment-followup. [19] BBB disruption imaging was shown capacity in animal model to serve as a biomarker of epileptogenesis [20] and specific EEG patterns were also shown to predict epilepsy in several models. [21]

History

Throughout most of history for which written records exist on the subject, it was probably generally believed that epilepsy came about through a supernatural process. [22] Even within the medical profession, it was not until the 18th century that ideas of epileptogenesis as a supernatural phenomenon were abandoned. [22] However, biological explanations have also long existed, and sometimes explanations contained both biological and supernatural elements. [22]

Research

Epileptogenesis that occurs in human brains has been modeled in a variety of animal models and cell culture models. [2] Epileptogenesis is poorly understood, [6] and increasing understanding of the process may aid researchers in preventing seizures, diagnosing epilepsy, [23] and developing treatments to prevent it. [2]

See also

Related Research Articles

<span class="mw-page-title-main">Seizure</span> Period of symptoms due to excessive or synchronous neuronal brain activity

An epileptic seizure, informally known as a seizure, is a period of symptoms due to abnormally excessive or synchronous neuronal activity in the brain. Outward effects vary from uncontrolled shaking movements involving much of the body with loss of consciousness, to shaking movements involving only part of the body with variable levels of consciousness, to a subtle momentary loss of awareness. Most of the time these episodes last less than two minutes and it takes some time to return to normal. Loss of bladder control may occur.

<span class="mw-page-title-main">AMPA receptor</span> Transmembrane protein family

The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor is an ionotropic transmembrane receptor for glutamate (iGluR) that mediates fast synaptic transmission in the central nervous system (CNS). It has been traditionally classified as a non-NMDA-type receptor, along with the kainate receptor. Its name is derived from its ability to be activated by the artificial glutamate analog AMPA. The receptor was first named the "quisqualate receptor" by Watkins and colleagues after a naturally occurring agonist quisqualate and was only later given the label "AMPA receptor" after the selective agonist developed by Tage Honore and colleagues at the Royal Danish School of Pharmacy in Copenhagen. The GRIA2-encoded AMPA receptor ligand binding core was the first glutamate receptor ion channel domain to be crystallized.

<span class="mw-page-title-main">Excitotoxicity</span> Process that kills nerve cells

In excitotoxicity, nerve cells suffer damage or death when the levels of otherwise necessary and safe neurotransmitters such as glutamate become pathologically high, resulting in excessive stimulation of receptors. For example, when glutamate receptors such as the NMDA receptor or AMPA receptor encounter excessive levels of the excitatory neurotransmitter, glutamate, significant neuronal damage might ensue. Excess glutamate allows high levels of calcium ions (Ca2+) to enter the cell. Ca2+ influx into cells activates a number of enzymes, including phospholipases, endonucleases, and proteases such as calpain. These enzymes go on to damage cell structures such as components of the cytoskeleton, membrane, and DNA. In evolved, complex adaptive systems such as biological life it must be understood that mechanisms are rarely, if ever, simplistically direct. For example, NMDA in subtoxic amounts induces neuronal survival of otherwise toxic levels of glutamate.

<span class="mw-page-title-main">Dizocilpine</span> Chemical compound

Dizocilpine (INN), also known as MK-801, is a pore blocker of the N-Methyl-D-aspartate (NMDA) receptor, a glutamate receptor, discovered by a team at Merck in 1982. Glutamate is the brain's primary excitatory neurotransmitter. The channel is normally blocked with a magnesium ion and requires depolarization of the neuron to remove the magnesium and allow the glutamate to open the channel, causing an influx of calcium, which then leads to subsequent depolarization. Dizocilpine binds inside the ion channel of the receptor at several of PCP's binding sites thus preventing the flow of ions, including calcium (Ca2+), through the channel. Dizocilpine blocks NMDA receptors in a use- and voltage-dependent manner, since the channel must open for the drug to bind inside it. The drug acts as a potent anti-convulsant and probably has dissociative anesthetic properties, but it is not used clinically for this purpose because of the discovery of brain lesions, called Olney's lesions (see below), in laboratory rats. Dizocilpine is also associated with a number of negative side effects, including cognitive disruption and psychotic-spectrum reactions. It inhibits the induction of long term potentiation and has been found to impair the acquisition of difficult, but not easy, learning tasks in rats and primates. Because of these effects of dizocilpine, the NMDA receptor pore blocker ketamine is used instead as a dissociative anesthetic in human medical procedures. While ketamine may also trigger temporary psychosis in certain individuals, its short half-life and lower potency make it a much safer clinical option. However, dizocilpine is the most frequently used uncompetitive NMDA receptor antagonist in animal models to mimic psychosis for experimental purposes.

<span class="mw-page-title-main">Kainate receptor</span> Class of ionotropic glutamate receptors

Kainate receptors, or kainic acid receptors (KARs), are ionotropic receptors that respond to the neurotransmitter glutamate. They were first identified as a distinct receptor type through their selective activation by the agonist kainate, a drug first isolated from the algae Digenea simplex. They have been traditionally classified as a non-NMDA-type receptor, along with the AMPA receptor. KARs are less understood than AMPA and NMDA receptors, the other ionotropic glutamate receptors. Postsynaptic kainate receptors are involved in excitatory neurotransmission. Presynaptic kainate receptors have been implicated in inhibitory neurotransmission by modulating release of the inhibitory neurotransmitter GABA through a presynaptic mechanism.

<span class="mw-page-title-main">Kainic acid</span> Chemical compound

Kainic acid, or kainate, is an acid that naturally occurs in some seaweed. Kainic acid is a potent neuroexcitatory amino acid agonist that acts by activating receptors for glutamate, the principal excitatory neurotransmitter in the central nervous system. Glutamate is produced by the cell's metabolic processes and there are four major classifications of glutamate receptors: NMDA receptors, AMPA receptors, kainate receptors, and the metabotropic glutamate receptors. Kainic acid is an agonist for kainate receptors, a type of ionotropic glutamate receptor. Kainate receptors likely control a sodium channel that produces excitatory postsynaptic potentials (EPSPs) when glutamate binds.

<span class="mw-page-title-main">Glutamate receptor</span> Cell-surface proteins that bind glutamate and trigger changes which influence the behavior of cells

Glutamate receptors are synaptic and non synaptic receptors located primarily on the membranes of neuronal and glial cells. Glutamate is abundant in the human body, but particularly in the nervous system and especially prominent in the human brain where it is the body's most prominent neurotransmitter, the brain's main excitatory neurotransmitter, and also the precursor for GABA, the brain's main inhibitory neurotransmitter. Glutamate receptors are responsible for the glutamate-mediated postsynaptic excitation of neural cells, and are important for neural communication, memory formation, learning, and regulation.

<span class="mw-page-title-main">Temporal lobe epilepsy</span> Chronic focal seizure disorder

In the field of neurology, temporal lobe epilepsy is an enduring brain disorder that causes unprovoked seizures from the temporal lobe. Temporal lobe epilepsy is the most common type of focal onset epilepsy among adults. Seizure symptoms and behavior distinguish seizures arising from the medial temporal lobe from seizures arising from the lateral (neocortical) temporal lobe. Memory and psychiatric comorbidities may occur. Diagnosis relies on electroencephalographic (EEG) and neuroimaging studies. Anticonvulsant medications, epilepsy surgery and dietary treatments may improve seizure control.

<span class="mw-page-title-main">Quisqualic acid</span> Chemical compound

Quisqualic acid is an agonist of the AMPA, kainate, and group I metabotropic glutamate receptors. It is one of the most potent AMPA receptor agonists known. It causes excitotoxicity and is used in neuroscience to selectively destroy neurons in the brain or spinal cord. Quisqualic acid occurs naturally in the seeds of Quisqualis species.

Post-traumatic epilepsy (PTE) is a form of acquired epilepsy that results from brain damage caused by physical trauma to the brain. A person with PTE experiences repeated post-traumatic seizures more than a week after the initial injury. PTE is estimated to constitute 5% of all cases of epilepsy and over 20% of cases of acquired epilepsy.

<span class="mw-page-title-main">Spike-and-wave</span>

Spike-and-wave is a pattern of the electroencephalogram (EEG) typically observed during epileptic seizures. A spike-and-wave discharge is a regular, symmetrical, generalized EEG pattern seen particularly during absence epilepsy, also known as ‘petit mal’ epilepsy. The basic mechanisms underlying these patterns are complex and involve part of the cerebral cortex, the thalamocortical network, and intrinsic neuronal mechanisms.

A convulsant is a drug which induces convulsions and/or epileptic seizures, the opposite of an anticonvulsant. These drugs generally act as stimulants at low doses, but are not used for this purpose due to the risk of convulsions and consequent excitotoxicity. Most convulsants are antagonists at either the GABAA or glycine receptors, or ionotropic glutamate receptor agonists. Many other drugs may cause convulsions as a side effect at high doses but only drugs whose primary action is to cause convulsions are known as convulsants. Nerve agents such as sarin, which were developed as chemical weapons, produce convulsions as a major part of their toxidrome, but also produce a number of other effects in the body and are usually classified separately. Dieldrin which was developed as an insecticide blocks chloride influx into the neurons causing hyperexcitability of the CNS and convulsions. The Irwin observation test and other studies that record clinical signs are used to test the potential for a drug to induce convulsions. Camphor, and other terpenes given to children with colds can act as convulsants in children who have had febrile seizures.

GABA transporters (Gamma-Aminobutyric acid transporters) belong to the family of neurotransmitters known as sodium symporters, also known as solute carrier 6 (SLC6). These are large family of neurotransmitter which are Na+ concentration dependent. They are found in various regions of the brain in different cell types, such as neurons and astrocytes.

<span class="mw-page-title-main">Methylazoxymethanol acetate</span> Chemical compound

Methylazoxymethanol acetate, MAM, is a neurotoxin which reduces DNA synthesis used in making animal models of neurological diseases including schizophrenia and epilepsy. MAM is found in cycad seeds, and causes zamia staggers. It selectively targets neuroblasts in the central nervous system. In rats, administration of MAM affects structures in the brain which are developing most quickly. It is an acetate of methylazoxymethanol.

James O. McNamara is an American neurologist and neuroscientist, known for his research of epileptogenesis, the process underlying development and progression of epilepsy. He is the Duke School of Medicine Professor of Neuroscience in the Departments of Neurobiology, Neurology, and Pharmacology and Cancer Biology at Duke University. He served as chair of the Department of Neurobiology at Duke from 2002 to 2011

Gene therapy is being studied for some forms of epilepsy. It relies on viral or non-viral vectors to deliver DNA or RNA to target brain areas where seizures arise, in order to prevent the development of epilepsy or to reduce the frequency and/or severity of seizures. Gene therapy has delivered promising results in early stage clinical trials for other neurological disorders such as Parkinson's disease, raising the hope that it will become a treatment for intractable epilepsy.

<span class="mw-page-title-main">Alon Friedman</span> Israeli neuroscientist

Alon Friedman is a professor of Neuroscience at both Ben-Gurion University of the Negev (BGU) in Beersheba, Israel, and in Dalhousie University, Halifax, Nova Scotia, Canada. He is best known for his discoveries of the link between blood–brain barrier (BBB) disruption and Epileptogenesis and the mechanisms underlying it, and for the utilization of BBB imaging as a potential Biomarker of epilepsy and other brain diseases.

<span class="mw-page-title-main">Willardiine</span> Chemical compound

Willardiine (correctly spelled with two successive i's) or (S)-1-(2-amino-2-carboxyethyl)pyrimidine-2,4-dione is a chemical compound that occurs naturally in the seeds of Mariosousa willardiana and Acacia sensu lato. The seedlings of these plants contain enzymes capable of complex chemical substitutions that result in the formation of free amino acids (See: #Synthesis). Willardiine is frequently studied for its function in higher level plants. Additionally, many derivates of willardiine are researched for their potential in pharmaceutical development. Willardiine was first discovered in 1959 by R. Gmelin, when he isolated several free, non-protein amino acids from Acacia willardiana (another name for Mariosousa willardiana) when he was studying how these families of plants synthesize uracilyalanines. A related compound, Isowillardiine, was concurrently isolated by a different group, and it was discovered that the two compounds had different structural and functional properties. Subsequent research on willardiine has focused on the functional significance of different substitutions at the nitrogen group and the development of analogs of willardiine with different pharmacokinetic properties. In general, Willardiine is the one of the first compounds studied in which slight changes to molecular structure result in compounds with significantly different pharmacokinetic properties.

<span class="mw-page-title-main">LSP2-9166</span>

LSP2-9166 is a drug which acts as a selective agonist for the group III metabotropic glutamate receptors, with a reasonably potent EC50 of 70nM at mGluR4 and 220nM at mGluR7, and weaker activity of 1380nM at mGluR6 and 4800nM at mGluR8. It has anticonvulsant effects in animal studies, and reduces self-administration of various addictive drugs.

<span class="mw-page-title-main">Raymond Dingledine</span> American harmacologist, neurobiologist (born 1948)

Raymond J Dingledine is an American pharmacologist and neurobiologist who has made considerable contributions to the field of epilepsy. He serves as Professor in the School of Medicine at Emory University, Atlanta GA, where he chaired the pharmacology department for 25 years and served as Executive Associate Dean of Research for 10 years.

References

  1. ↑ Lukasiuk, K. (2014). "Epileptogenesis". In Aminoff, Michael J; Daroff, Robert B (eds.). Encyclopedia of the Neurological Sciences (Second Edition). Vol. 2 (Second ed.). London: Academic Press. pp. 196–199. ISBN   978-0-12-385157-4.
  2. 1 2 3 4 5 McNamara JO, Huang YZ, Leonard AS (October 2006). "Molecular signaling mechanisms underlying epileptogenesis". Sci. STKE. 2006 (356): re12. doi:10.1126/stke.3562006re12. PMID   17033045. S2CID   42882078.
  3. 1 2 3 4 5 Armijo JA, Valdizán EM, De Las Cuevas I, Cuadrado A (2002). "Advances in the physiopathology of epileptogenesis: Molecular aspects". Rev Neurol (in Spanish). 34 (5): 409–29. PMID   12040510.
  4. ↑ Noebels, Jeffrey L.; Avoli, Massimo (2012-06-29). Jasper's Basic Mechanisms of the Epilepsies. Oxford University Press. p. 3. ISBN   9780199746545 . Retrieved 2014-10-16.
  5. 1 2 3 Herman ST (January 2006). "Clinical trials for prevention of epileptogenesis". Epilepsy Res. 68 (1): 35–8. doi:10.1016/j.eplepsyres.2005.09.015. PMID   16377141. S2CID   46017678.
  6. 1 2 3 4 5 6 7 8 9 10 Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF (February 2008). "Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy". Epilepsy Res. 78 (2–3): 102–16. doi:10.1016/j.eplepsyres.2007.11.011. PMC   2272535 . PMID   18226499.
  7. ↑ "Post-traumatic epilepsy". Br Med J. 2 (6132): 229. 1978. doi:10.1136/bmj.2.6132.229. PMC   1606365 . PMID   98198.
  8. 1 2 Firlik KS, Spencer DD (2004). "Surgery of post-traumatic epilepsy". In Dodson WE, Avanzini G, Shorvon SD, Fish DR, Perucca E (eds.). The Treatment of Epilepsy. Oxford: Blackwell Science. p. 775. ISBN   0-632-06046-8 . Retrieved 2008-06-09.
  9. ↑ Schevon CA, Tobochnik S, Eissa T, Merricks E, Gill B, Parrish RR, Bateman LM, McKhann GM Jr, Emerson RG, Trevelyan AJ (2019). "Multiscale recordings reveal the dynamic spatial structure of human seizures". Neurobiol Dis. 127: 303–311. doi:10.1016/j.nbd.2019.03.015. PMC   6588430 . PMID   30898669.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ↑ Seiffert E, Dreier JP, Ivens S, Bechmann I, Heinemann U, Friedman A (2004). "Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J". Neuroscience. 24 (36): 7829–36. doi: 10.1523/JNEUROSCI.1751-04.2004 . PMC   6729929 . PMID   15356194.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ↑ van Vliet EA, da Costa Araujo S, Redeker S, van Schaik R, Aronica E, Gorter JA (2007). "Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy". Brain. 130 (2): 521–534. doi: 10.1093/brain/awl318 . PMID   17124188.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ↑ Ivens S, Kaufer D, Seiffert E, Bechmann I, Tomkins O, Heinemann U, Friedman A (2007). "TGF-beta receptor mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis". Brain. 130 (Pt 2): 535–47. doi: 10.1093/brain/awl317 . PMID   17121744.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. 1 2 Cacheaux LP, Ivens S, David Y, Lakhter AJ, Bar-Klein G, Shapira M, Heinemann U, Friedman A, Kaufer D (2009). "Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis". Journal of Neuroscience. 29 (28): 8927–8935. doi:10.1523/JNEUROSCI.0430-09.2009. PMC   2875073 . PMID   19605630.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ↑ David Y, Flores LP, Ivens S, Heinemann U, Kaufer D, Friedman A (2009). "Astrocytic dysfunction in epileptogenesis: consequences of altered potassium and glutamate buffering?". Journal of Neuroscience. 29 (34): 10588–99. doi:10.1523/JNEUROSCI.2323-09.2009. PMC   2875068 . PMID   19710312.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ↑ Levy N, Milikovsky DZ, Baranauskas G, Vinogradov E, David Y, Ketzef M, Abutbul S, Weissberg I, Kamintsky L, Fleidervish I, Friedman A, Monsonego A (2015). "Differential TGF-β Signaling in Glial Subsets Underlies IL-6-Mediated Epileptogenesis in Mice". J Immunol. 195 (4): 1713–22. doi: 10.4049/jimmunol.1401446 . PMID   26136430.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ↑ Weissberg I, Wood L, Kamintsky L, Vazquez O, Milikovsky DZ, Alexander A, Oppenheim H, Ardizzone C, Becker A, Frigerio F, Vezzani A, Buckwalter MS, Huguenard JR, Friedman A, Kaufer D (2015). "Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction". Neurobiol Dis. 78: 115–25. doi:10.1016/j.nbd.2015.02.029. PMC   4426044 . PMID   25836421.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ↑ Beghi E (2004). "Aetiology of epilepsy". In Dodson WE, Avanzini G, Shorvon SD, Fish DR, Perucca E (eds.). The Treatment of Epilepsy. Oxford: Blackwell Science. p. 61. ISBN   0-632-06046-8 . Retrieved 2008-06-09.
  18. ↑ Kaminski, R. M.; Rogawski, M. A.; Klitgaard, H (2014). "The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments". Neurotherapeutics. 11 (2): 385–400. doi:10.1007/s13311-014-0266-1. PMC   3996125 . PMID   24671870.
  19. ↑ Friedman A, Bar-Klein G, Serlin Y, Parmet Y, Heinemann U, Kaufer D (2014). "Should losartan be administered following brain injury?". Expert Rev Neurother. 14 (12): 1365–75. doi:10.1586/14737175.2014.972945. PMID   25346269. S2CID   207193826.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  20. ↑ Bar-Klein G, Lublinsky S, Kamintsky L, Noyman I, Veksler R, Dalipaj H, Senatorov VV Jr, Swissa E, Rosenbach D, Elazary N, Milikovsky DZ, Milk N, Kassirer M, Rosman Y, Serlin Y, Eisenkraft A, Chassidim Y, Parmet Y, Kaufer D, Friedman A (2017). "Imaging blood-brain barrier dysfunction as a biomarker for epileptogenesis". Brain. 140 (6): 1692–1705. doi: 10.1093/brain/awx073 . PMID   28444141.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  21. ↑ Milikovsky DZ, Weissberg I, Kamintsky L, Lippmann K, Schefenbauer O, Frigerio F, Rizzi M, Sheintuch L, Zelig D, Ofer J, Vezzani A, Friedman A (2017). "Electrocorticographic Dynamics as a Novel Biomarker in Five Models of Epileptogenesis". J Neurosci. 37 (17): 4450–4461. doi:10.1523/JNEUROSCI.2446-16.2017. PMC   6596657 . PMID   28330876.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  22. 1 2 3 Eadie MJ, Bladin PF (2001). "The interpretation of the epileptic process". A Disease Once Sacred: A History of the Medical Understanding of Epilepsy. London: John Libbey. p. 80. ISBN   0-86196-607-4 . Retrieved 2008-06-12.
  23. ↑ Leśkiewicz M, Lasoń W (2007). "The neurochemical mechanisms of temporal lobe epilepsy: an update". Prz. Lek. (in Polish). 64 (11): 960–4. PMID   18409413.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.